PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy (PROPS)
PROPS (PET/MRI Pre-Radiotherapy for Post-Prostatectomy Salvage)
The PROPS trial is for men being considered for radiotherapy due to the suspicion that their prostate cancer has recurred following the surgical removal of their prostate (prostatectomy). This suspicion is based on rises seen on Prostate Specific Antigen (PSA) blood tests. Only men who demonstrate the absence of disease on standard imaging scans (Computed Tomography (CT) and bone scans) will be invited to participate.
This study will be assessing if the imaging probe 18-F Fluorocholine (18F-FCH) used during Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) scans, can better predict who will benefit from radiotherapy by identifying the source of cancer recurrence. This will be determined by measuring the number of men who have disease identified outside of the prostate bed (the small pocket or depression where the prostate used to be) on their 18F-FCH PET scan. Since F-18-FCH has been shown to be more sensitive in detecting prostate cancer that may have spread into lymph nodes or bone, it may potentially identify areas of prostate cancer spread not seen with standard imaging.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study will be a non-randomized, prospective study of men with suspected local recurrence of prostate cancer post-prostatectomy with negative conventional re-staging studies (bone scan and CT of the abdomen and pelvis; MRI of the pelvis as part of re-staging is allowed where it is the institutional standard of care). The clinician will develop an initial treatment plan based on conventional re-staging information.
Patients enrolled onto trial will undergo hybrid PET/MR imaging using 18F-FCH (sites without access to a hybrid PET/MR scanner will conduct a 18F-FCH PET/CT in addition to a full body MRI). A consensus staging report based on local and centralized review of the 18F-FCH PET imaging will be provided to the attending clinician, who will document a second treatment plan based on this additional information. The treatment plan to be implemented (initial or second) will be left to clinician discretion, but will be documented.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2010
- St. Vincent's Hospital
-
-
Victoria
-
Melbourne, Victoria, Australie, 3002
- Peter MacCallum Cancer Centre
-
Melbourne, Victoria, Australie, 3084
- Austin Hospital
-
Melbourne, Victoria, Australie, 3128
- Eastern Health
-
-
-
-
Ontario
-
London, Ontario, Canada, N6A 5W9
- Lawson Health Research Institute, London Health Sciences Centre
-
Toronto, Ontario, Canada, M5G 2M9
- University of Toronto
-
-
Quebec
-
Laval, Quebec, Canada, G1V 0A6
- Université Laval Quebec
-
-
-
-
-
London, Royaume-Uni, SW3 6JJ
- Royal Marsden Hospital
-
London, Royaume-Uni, NW1 2BU
- University College London Hospital
-
-
South Glamorgan
-
Cardiff, South Glamorgan, Royaume-Uni
- Velindre Cancer Centre
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Male, aged 18 years or older.
- Confirmation of prostate cancer on prostatectomy pathology report.
- No lymph node involvement (N0 or Nx) reported on prostatectomy pathology report.
- Documented PSA rise measured on 3 occasions.
- PSA ≥ 0.2 ng/ml at enrolment.
- At least one adverse feature: Current PSA > or equal to 1.0, Initial Gleason Grade > or equal to 8, Positive surgical margin, pT3b (seminal vesicle involvement), or PSA doubling time < 10 months.
- Bone scan and CT scan within 12 weeks of enrolment negative or equivocal for metastatic disease.
- Suitable candidate for radiotherapy and not yet had any salvage treatment post-prostatectomy.
Exclusion Criteria:
- Prostate cancer with significant sarcomatoid or spindle cell or neuroendocrine small cell components.
- Proven metastatic disease.
- Patients who refuse salvage prostate bed radiotherapy.
- Patients who refuse to join the trial or are unable to consent.
- Patients not being considered for further therapy.
- Patients who cannot lie still for at least 30 minutes or comply with imaging.
- Unequivocal evidence of disease outside the prostate bed on conventional imaging
- Allergy to MRI contrast agent (exclusion for MRI component only) or PET tracer to be used as part of the imaging
- Sickle cell disease or other anemias
- Insufficient renal function (eGFR < 30 mL/min/1.73 m2)
- Residual bladder volume > 150 cc (determined by post-void ultrasound)
- Hip prosthesis, vascular grafting or other conditions affecting imaging or delivery of therapeutic radiation
- Contraindication to MRI, including but not restricted to: pacemaker or other electronic implants, known metal in the orbit, MR incompatible surgical or cerebral aneurysm clips, Shrapnel, tattoos, non-removable body piercings (relative contraindications)
- Hormone Androgen deprivation therapy of any type within 6 months prior to enrollment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: 18F-FCH PET/MRI Scan
Patients will undergo an injection of 18F-fluoromethyl-choline at 3.6 MBq/kg followed by whole body PET/CT imaging.
Patients will also undergo a whole body MRI including T2 weighted, Diffusion weighted and Gadolinium Contrast Enhanced sequences.
Patients with suspicion for recurrence may undergo biopsy if lesions identified on PET/CT or MRI are accessible for biopsy
|
Patients will first undergo screening to ensure eligibility.
If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer.
If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Proportion of men with negative or equivocal conventional restaging imaging (bone scan + CT scan of abdomen and pelvis) with uptake identified outside of the prostate bed on 18F-FCH PET
Délai: Within 2 weeks of 18F-FCH PET scan
|
Within 2 weeks of 18F-FCH PET scan
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Biochemical disease free survival at 3 years post-treatment
Délai: 3 years post-treatment
|
Whether biochemical (PSA) control rates 3 years post-treatment are improved for participants with 18F-FCH PET imaging that was negative or demonstrated uptake confined to the prostate bed and received salvage pelvic radiotherapy compared to published results for men with adverse features.
|
3 years post-treatment
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Glenn Bauman, MD, London Regional Cancer Program
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GAP02-01.1
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .